GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GFC Life Science Co Ltd (XKRX:388610) » Definitions » Debt-to-EBITDA

GFC Life Science Co (XKRX:388610) Debt-to-EBITDA : -2.64 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is GFC Life Science Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

GFC Life Science Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩5,428 Mil. GFC Life Science Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩1,594 Mil. GFC Life Science Co's annualized EBITDA for the quarter that ended in Dec. 2024 was ₩-2,656 Mil. GFC Life Science Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -2.64.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for GFC Life Science Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:388610' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.64   Med: -0.68   Max: 1.29
Current: -2.64

During the past 2 years, the highest Debt-to-EBITDA Ratio of GFC Life Science Co was 1.29. The lowest was -2.64. And the median was -0.68.

XKRX:388610's Debt-to-EBITDA is ranked worse than
100% of 284 companies
in the Biotechnology industry
Industry Median: 1.395 vs XKRX:388610: -2.64

GFC Life Science Co Debt-to-EBITDA Historical Data

The historical data trend for GFC Life Science Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GFC Life Science Co Debt-to-EBITDA Chart

GFC Life Science Co Annual Data
Trend Dec23 Dec24
Debt-to-EBITDA
1.29 -2.64

GFC Life Science Co Semi-Annual Data
Dec23 Dec24
Debt-to-EBITDA 1.29 -2.64

Competitive Comparison of GFC Life Science Co's Debt-to-EBITDA

For the Biotechnology subindustry, GFC Life Science Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GFC Life Science Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GFC Life Science Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where GFC Life Science Co's Debt-to-EBITDA falls into.


;
;

GFC Life Science Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

GFC Life Science Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5427.995 + 1594.089) / -2655.507
=-2.64

GFC Life Science Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5427.995 + 1594.089) / -2655.507
=-2.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (Dec. 2024) EBITDA data.


GFC Life Science Co  (XKRX:388610) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


GFC Life Science Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of GFC Life Science Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


GFC Life Science Co Business Description

Traded in Other Exchanges
N/A
Address
823, Dongtansunhwan-daero, 17th Floor, Gyeonggi-do, Hwaseong-si, KOR
GFC Life Science Co Ltd develops innovative cosmetics using a variety of sources. The company's ingredients specialize in human biotechnology, Bio-Phytochemistry, research of Bio-Fermentation, Unique Bio-Technology, anti-pollution material, and powder transfer technology.

GFC Life Science Co Headlines

No Headlines